Retrospective Review of Esophageal Cancer at MSKCC

Recruiting

• Conditions: Esophageal Cancer; Esophagus Cancer

• Registration Number: NCT05706558
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-1-23
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 4000

Inclusion Criteria

Inclusion Criteria:<br><br> - Histologically confirmed esophageal adenocarcinoma (EAC) or esophageal squamous cell<br> carcinoma (ESCC) undergoing esophagectomy<br><br> - Pathologic staged T3 tumors (pT3)<br><br>Exclusion Criteria:<br><br> - Pathologic staged T0-2 (pT0-2) or T4 tumors (pT4)<br><br> - Patients with histologic types other than EAC or ESCC, dysplasia or carcinoma in<br> situ without tumor invasion,<br><br> - Patients undergoing salvage esophagectomy<br><br> - Evidence of distant metastatic disease<br><br> - Patients with a positive proximal or distal margin

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
. Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery)

Secondary Outcome Measures

Name	Time	Method
Overall survival and progression-free survival (measured from date of surgery);Postoperative outcomes stratified by the time between neoadjuvant therapy and surgery (i.e., delayed or immediate).;Survival outcomes stratified by treatment modality (i.e., definitive chemoradiation therapy or trimodality treatment).;Survival outcomes stratified by use of adjuvant therapy (i.e., adjuvant therapy or no adjuvant therapy).